Aspira Women’s Health Inc. has entered into a new laboratory services agreement with the University of Texas Medical Branch at Galveston as part of its strategy to expand access to its ovarian cancer diagnostic tests across Texas.
Aspira Women’s Health Inc., a bio-analytical company focused on gynecologic disease diagnostics, has entered into a new 12-month laboratory services agreement with the University of Texas Medical Branch at Galveston, officials revealed on Thursday.
The collaboration represents a notable advancement in Aspira’s mission to broaden its presence in Texas and promote the use of its ovarian cancer diagnostic tests, Ova1Plus® and OvaWatch®. The agreement aligns with the company’s marketing strategy of collaborating with major healthcare organizations to connect with thousands of patients and providers effectively.
“I am excited to share the addition of a highly esteemed client on behalf of our team,” stated Aspira CEO Mike Buhle. “Transforming and enhancing our go-to-market strategy has been a key focus for us.” Our collaboration with the University of Texas Medical Branch at Galveston underscores our commitment to leveraging technology and strategic partnerships to expand patient outreach and make a meaningful difference in women’s health.
Aspira’s Ova1Plus® and OvaWatch® tests, collectively referred to as OvaSuiteSM, are intended to assist healthcare professionals in evaluating the risk of ovarian cancer in women who have been diagnosed with adnexal masses. OvaWatch® has an impressive 99% accuracy in identifying patients whose masses are unlikely to be cancerous, helping reduce the number of unnecessary surgeries. Ova1Plus® integrates two FDA-cleared assessments—Ova1® and Overa®—toevaluate the risk of malignancy in women preparing for surgery.
The company said it is working on improved diagnostic tools that combine microRNA and protein biomarkers with patient information to improve the accuracy of ovarian cancer detection. Aspira is making strides in research focused on noninvasive tests for endometriosis, a chronic and painful condition that impacts millions of women around the world.
Located in Austin, Aspira Women’s Health is dedicated to developing noninvasive diagnostics for gynecologic diseases using the power of artificial intelligence. The organization announced that the recent partnership with UTMB Galveston enhances its footprint in Texas and aligns with its goal of advancing early detection and outcomes in women's health.
